Citation

Verlut C, Mouillet G, Magnin E, Buffet-Miny J, Viennet G, Cattin F, Billon-Grand NC, Bonnet E, Servagi-Vernat S, Godard J, Billon-Grand R, Petit A, Moulin T, Cals L, Pivot X, Curtit E. Clinical Medicine Insights: Oncology 2016; 10: 77-82.

Copyright

(Copyright © 2016)

DOI

10.4137/CMO.S38474

PMID

unavailable

Abstract

INTRODUCTION: Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution.

METHODS: This retrospective study included all patients with histologically proven glioblastoma diagnosed between June 1, 2005, and January 1, 2012, in the Franche-Comté region and treated by radiotherapy (daily fractions of 2 Gy for a total of 60 Gy) combined with temozolomide at a dose of 75 mg/m2 per day, followed by six cycles of maintenance temozolomide (150-200 mg/m2, five consecutive days per month). The primary aim was to identify prognostic factors associated with overall survival (OS) in this cohort of patients.

RESULTS: One hundred three patients were included in this study. The median age was 64 years. The median OS was 13.7 months (95% confidence interval, 12.5-15.9 months). In multivariate analysis, age over 65 years (hazard ratio [HR] = 1.88; P = 0.01), Medical Research Council (MRC) scale 3-4 (HR = 1.62; P = 0.038), and occurrence of postoperative complications (HR = 2.15; P = 0.028) were associated with unfavorable OS.

CONCLUSIONS: This study identified three prognostic factors in patients with glioblastoma eligible to the standard chemotherapy and radiotherapy treatment. Age over 65 years, MRC scale 3-4, and occurrence of postoperative complications were associated with unfavorable OS. A simple clinical evalu-ation including these three factors enables to estimate the patient prognosis. MRC neurological scale could be a useful, quick, and simple measure to assess neurological status in glioblastoma patients. © the authors, publisher and licensee Libertas Academica Limited.

Language: en

Keywords

adult; human; age; female; male; prognosis; aged; France; suicide attempt; morbidity; fatigue; major clinical study; retrospective study; human tissue; glioblastoma; neutropenia; temozolomide; thrombocytopenia; headache; multivariate analysis; cancer surgery; infection; alopecia; postoperative complication; neurologic examination; Article; overall survival; maintenance drug dose; multiple cycle treatment; chemoradiotherapy; very elderly; Temozolomide; Chemoradiotherapy; Glioblastoma; MRC neurological status; neurological status Medical Research Council scale; tumor biopsy